Cambridge Antibody Technology Report issue

For profit Phase 1 Phase 2
Founded: Cambridge United Kingdom (1989)
Status: Acquired by AstraZeneca (2006)

Organization Overview

First Clinical Trial
2002
NCT00043706
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

metelimumab (1 trial)

tralokinumab (Adtralza) (1 trial)

Drugs in Phase 1 Trials (2)

bl22 (1 trial)

moxetumomab pasudotox (Lumoxiti) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Leukemia (Phase 1)

Leukemia, Hairy Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Prolymphocytic (Phase 1)

Lymphoma (Phase 1)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 4